alexa Discovery of a Small Molecule in the Treatment Development of Pancreatic Cancer | Open Access Journals
ISSN: 2167-7700
Chemotherapy: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Discovery of a Small Molecule in the Treatment Development of Pancreatic Cancer

Zuojia Liu* and Jin Wang

State Key Laboratory of Electro Analytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, PR China

*Corresponding Author:
Zuojia Liu
State Key Laboratory of Electro Analytical Chemistry
Changchun Institute of Applied Chemistry
Chinese Academy of Sciences, Changchun, Jilin, PR China
Tel: +6084405142
E-mail: [email protected]

Received date: March 15, 2017; Accepted date: May 23, 2017; Published date: May 29, 2017

Citation: Liu Z, Wang J (2017) Discovery of a Small Molecule in the Treatment Development of Pancreatic Cancer. Chemo Open Access 6:234. doi: 10.4172/2167-7700.1000234

Copyright: © 2017 Liu Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemotherapy: Open Access

Abstract

KRas gene is the most essential oncogene in human cancer, and the oncogenic mutations are found in approximately 90% of patients with pancreatic cancer. However, effective therapies for these patients are unavailable currently. In general, multiple cellular processes are affected by the oncogenic Ras mutants via exploiting their extensive signaling, in which the Ras-MAPK signaling cascade exerts important roles. Thus, targeted-Ras therapies are beneficial for the treatment of pancreatic cancer. Using an innovative SPA (Specificity and Affinity) drug screening strategy (which searches for potential lead compounds reaching the maximization of the performances on the binding affinity and binding specificity predictions), which begun four years ago, the CIAC researchers have identified a core of 26 small-molecule agents targeted KRas oncoprotein from NCI/DTP Open Chemical Repository [2]. From these agents, the researchers were interested in focusing on APY606 since the fact was uncovered that in pancreatic cancer, "its anti-cancer property is the most promissing", explained Dr. Zuojia Liu, a researcher at CIAC. In the studies, the researchers assessed the effect of APY606 on antitumor activity against human pancreatic cancer cell lines, Capan-1 and SW1990, and on the Ras-MAPK and apoptosisrelated signaling cascades. The combined data suggest that APY606 exerts extensive antitumor activities for the therapeutic intervention in

Keywords

Pancreatic cancer; KRas gene; Binding affinity; Patients

Commentary

Researchers at the State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry (CIAC), Chinese Academy of Sciences, have identified a promising small-molecule APY606 in the treatment development of pancreatic cancer via attenuating the Ras-mitogen-activated protein kinase (Ras-MAPK) signaling cascade. This work collaborated with researcher at State University of New York, Stony Brook has been published in the scientific journal PLoS ONE [1].

KRas gene is the most essential oncogene in human cancer, and the oncogenic mutations are found in approximately 90% of patients with pancreatic cancer. However, effective therapies for these patients are unavailable currently. In general, multiple cellular processes are affected by the oncogenic Ras mutants via exploiting their extensive signaling, in which the Ras-MAPK signaling cascade exerts important roles. Thus, targeted-Ras therapies are beneficial for the treatment of pancreatic cancer. Using an innovative SPA (Specificity and Affinity) drug screening strategy (which searches for potential lead compounds reaching the maximization of the performances on the binding affinity and binding specificity predictions), which begun four years ago, the CIAC researchers have identified a core of 26 small-molecule agents targeted KRas oncoprotein from NCI/DTP Open Chemical Repository [2]. From these agents, the researchers were interested in focusing on APY606 since the fact was uncovered that in pancreatic cancer, "its anti-cancer property is the most promissing", explained Dr. Zuojia Liu, a researcher at CIAC. In the studies, the researchers assessed the effect of APY606 on antitumor activity against human pancreatic cancer cell lines, Capan-1 and SW1990, and on the Ras-MAPK and apoptosis-related signaling cascades. The combined data suggest that APY606 exerts extensive antitumor activities for the therapeutic intervention in pancreatic cancer through attenuating the Ras-MAPK signaling cascade.

Accordingly, APY606 treatment of both cancer cells resulted in an inhibition of cancer cell viability at a dose- and time dependent manner. In addition, APY606 exhibited strong inhibitions in tumor cell invasion and migration and significant decrease of mitochondrial membrane potential by altering the expression levels of several apoptotic indexes. "What is most important is that inhibition of KRas activity brings about a great reduction in the cell viability and growth in the pancreatic cancer. Thus, the results present this agent as a new small molecule targeted KRas oncoprotein should be directed", the researcher added.

"The next step will be the identification in vivo. This step is critical, as not all patients are with mutated KRas; therefore xenograft models who may finally benefit from this treatment must be better defined", concluded the CIAC researchers.

Acknowledgement

Supported by National Natural Science Foundation of China (81573448) and Natural Science Foundation of Jilin Province (20150101009JC) for anticancer drug discovery program.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 227
  • [From(publication date):
    June-2017 - Sep 24, 2017]
  • Breakdown by view type
  • HTML page views : 192
  • PDF downloads :35
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords